{"prompt": "['NOVARTIS', 'Novartis Global Medical Affairs', 'QAW039', 'Clinical Trial Protocol CQAW039A2322/NCT03681093', 'A multicenter, randomized, double-blind, parallel-group,', 'placebo-controlled study of fevipiprant once daily plus', 'standard-of-care (SoC) for assessment of the efficacy in', 'reduction of nasal polyps size in patients with nasal', 'polyposis and concomitant asthma', 'Document type:', 'Amended Protocol Version', 'EUDRACT number:', '2018-002073-22', 'Version number:', '03 (Clean)', 'Clinical Trial Phase:', 'III', 'Release date:', '24-Sep-2019', 'Property of Novartis', 'Confidential', 'May not be used, divulged, published, or otherwise disclosed', 'without the consent of Novartis', 'Clinical Trial Protocol Template version 1.0 dated 01-Dec-2017']['Novartis', 'Confidential', 'Page 2', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Table of contents', 'Table of contents', '2', 'List of tables', '5', 'List of figures', '6', 'List of abbreviations', '7', 'Glossary of terms', '10', 'Amendment 3', '12', 'Amendment 2', '13', 'Amendment 1', '14', 'Protocol summary', '15', '1', 'Introduction', '18', '1.1', 'Background', '18', '1.2', 'Purpose', '19', '2', 'Objectives and endpoints', '19', '3', 'Study design', '20', '4', 'Rationale', '20', '4.1', 'Rationale for study design', '20', '4.1.1', 'Rationale for choice of background therapy', '21', '4.2', 'Rationale for dose/regimen and duration of treatment', '21', '4.3', 'Rationale for choice of control drugs (comparator/placebo) or combination', 'drugs', '21', '4.4', 'Purpose and timing of interim analyses/design adaptations', '21', '4.5', 'Risks and benefits', '22', '5 Population', '24', '5.1', 'Inclusion criteria', '24', '5.2', 'Exclusion criteria', '24', '6 Treatment', '28', '6.1', 'Study treatment', '28', '6.1.1', 'Investigational and control drugs', '28', '6.1.2', 'Additional study treatments', '28', '6.1.3', 'Treatment arms/group', '28', '6.1.4', 'Treatment duration', '29', '6.2', 'Other treatment(s)', '29']['Novartis', 'Confidential', 'Page 3', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '6.2.1', 'Concomitant therapy', '29', '6.2.2', 'Prohibited medication', '30', '6.2.3', 'Rescue medication', '31', '6.3', 'Subject numbering, treatment assignment, randomization', '31', '6.3.1', 'Subject numbering', '31', '6.3.2', 'Treatment assignment, randomization', '31', '6.4', 'Treatment blinding', '32', '6.5', 'Dose escalation and dose modification', '32', '6.5.1', 'Dose modifications', '33', '6.5.2', 'Follow-up for toxicities', '33', '6.6', 'Additional treatment guidance', '33', '6.6.1', 'Treatment compliance', '33', '6.6.2', 'Emergency breaking of assigned treatment code', '33', '6.7', 'Preparation and dispensation', '34', '6.7.1', 'Handling of study treatment and additional treatment', '34', '6.7.2', 'Instruction for prescribing and taking study treatment', '35', '7', 'Informed consent procedures', '36', '8', 'Visit schedule and assessments', '36', '8.1', 'Screening', '39', '8.1.1', 'Information to be collected on screening failures', '39', '8.2', 'Subject demographics/other baseline characteristics', '39', '8.3', 'Efficacy', '39', '8.3.1', 'Nasal Polyp Score', '40', '8.3.2', 'Patient Reported Outcomes', '40', '8.3.3', 'Smell (UPSIT)', '41', '8.3.4', 'Appropriateness of efficacy assessments', '41', '8.4', 'Safety', '41', '8.4.1', 'Laboratory evaluations', '42', '8.4.2', 'Electrocardiogram (ECG)', '42', '8.4.3', 'Pregnancy', '43', '8.4.4', 'Appropriateness of safety measurements', '43', '8.5', 'Additional assessments', '43', '8.5.1', 'Clinical Outcome Assessments (COAs)', '43']\n\n###\n\n", "completion": "END"}